表紙
市場調查報告書

膠原酶3:開發中產品分析

Collagenase 3 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 363134
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
膠原酶3:開發中產品分析 Collagenase 3 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 61 Pages
簡介

本報告提供膠原酶3藥物的開發情形相關資訊,提供您各開發階段,藥物標的,作用機制,給藥途徑及分子類型別分析,開發治療藥的企業概要,最新消息和新聞稿等資訊。

簡介

  • 調查範圍

膠原酶3概要

治療藥的開發

膠原酶3:開發中的產品 - 各開發階段

膠原酶3:開發中的產品 - 治療範圍別

膠原酶3:開發中的產品 - 各適應症

膠原酶3:開發中產品概況

  • 初期階段的產品

膠原酶3:企業開發中的產品

膠原酶3:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

膠原酶3治療藥的開發企業

  • Paradigm Biopharmaceuticals Limited
  • Pfizer Inc.
  • 武田藥品工業

膠原酶3:藥物簡介

膠原酶3:暫停中的計劃

膠原酶3:中止開發的產品

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2052TDB

Summary

According to the recently published report 'Collagenase 3 - Pipeline Review, H2 2019'; Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Collagenase-3 (MMP13) is a member of the matrix metalloproteinase (MMP) family of neutral endopeptidases. It plays a role in the degradation of extracellular matrix proteins including fibrillar collagen, fibronectin, TNC and ACAN, wound healing, tissue remodeling, cartilage degradation, bone development, bone mineralization and ossification.

The report 'Collagenase 3 - Pipeline Review, H2 2019' outlays comprehensive information on the Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Musculoskeletal Disorders, Cardiovascular, Central Nervous System, Genetic Disorders, Infectious Disease and Respiratory which include indications Osteoarthritis, Allergic Asthma, Alphavirus Infections, Arthralgia (Joint Pain), Arthritis, Chikungunya Fever, Congestive Heart Failure (Heart Failure), Edema, Knee Osteoarthritis, Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ), Myocardial Infarction, Osteoarthritis Pain and Seasonal Allergic Rhinitis.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • The report reviews Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Overview
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Companies Involved in Therapeutics Development
  • Aquilus Pharmaceuticals Inc
  • Paradigm Biopharmaceuticals Ltd
  • Pfizer Inc
  • Pharmahungary Group
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Drug Profiles
  • pentosan polysulfate sodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-152 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Proteins for Rheumatoid Arthritis and Osteoarthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP 2,9 and 13 for Myocardial Infarction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit MMP-13 for Osteoarthritis Pain and Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Dormant Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Discontinued Products
  • Collagenase 3 (Matrix Metalloproteinase 13 or MMP13 or EC 3.4.24.) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 30, 2019: Peer-reviewed publication confirms Paradigms ground-breaking discovery regarding new MOA for PPS
  • Sep 10, 2019: Paradigms first FDA IND is cleared within the 30-day review period
  • Aug 29, 2019: Paradigm discovers Zilosulo (iPPS) protects cartilage in knee osteoarthritis
  • Jun 04, 2019: Paradigm reports successful ross river phase 2a clinical trial
  • May 28, 2019: Paradigm reports positive RWE data for knee osteoarthritis therapeutic
  • Apr 16, 2019: Paradigm's knee osteoarthritis study meets secondary endpoints
  • Feb 14, 2019: Paradigm's orphan phase 2/3 clinical program progresses
  • Nov 07, 2018: Paradigms Osteoarthritis treatment maintains more than 50% knee pain reduction
  • Sep 25, 2018: Paradigm consistently shows greater than 50% knee pain reduction
  • Aug 28, 2018: Paradigm's phase 2 a Ross River virus clinical trial recruitment finalised
  • Aug 15, 2018: Paradigm achieves 60% reduction in osteoarthritis pain
  • Aug 06, 2018: Paradigm achieves 100% recruitment in Phase 2b Osteoarthritis Trial
  • May 17, 2018: Phase 2b Osteoarthritis Clinical Trial Ahead of Schedule with 80% Recruited
  • Mar 27, 2018: Paradigm Phase 2 Clinical Data - Update
  • Mar 01, 2018: Paradigm Reports Osteoarthritis Pain Reduced by 50%
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Aquilus Pharmaceuticals Inc, H2 2019
  • Pipeline by Paradigm Biopharmaceuticals Ltd, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Pharmahungary Group, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top